Health Insurance (1997-98 Pathology Services Table) Regulations (Cth)

Case
No judgment structure available for this case.

Health Insurance (1997-98 Pathology Services Table) Regulations

Statutory Rules 1997 No. 299 as amended

made under the

Health Insurance Act 1973

This compilation was prepared on 9 August 2001

taking into account amendments up to SR 1998 No. 203

[Note:

These regulations were repealed by SR 1998 No. 303]

Prepared by the Office of Legislative Drafting,

Attorney-General’s Department, Canberra

Contents

Page

  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
  • •
    1Citation [see Note 1]

 These Regulations may be cited as the Health Insurance (1997-98 Pathology Services Table) Regulations.

2Commencement

 These Regulations commence on 1 November 1997.

3Pathology services table

 The table of pathology services in the Schedule is prescribed for subsection 4A (1) of the Health Insurance Act 1973.

4Repeal of Health Insurance (1996-97 Pathology Services Table) Regulations

 Statutory Rules 1996 No. 232 and Statutory Rules 1997 No. 54 are repealed.

ScheduleTable of pathology service

(regulation 3)

Part1Rules of interpretation1Interpretation of Table

(1) In this Table:

patient episode means:

  • (a)

    a pathology service or pathology services (other than a pathology service to which paragraph (1) (b) refers) provided for a single patient whose need for the service or services was determined under subsection 16A of the Act:

    • (i)

      on the same day; or

    • (ii)

      if more than 1 test is performed on the 1 specimen within 14 days — on the same or different days.

 whether the services:

  • (iii)

    are requested by 1 or more practitioners; or

  • (iv)

    are described in a single item or in more than 1 item; or

  • (v)

    are rendered by 1 approved pathology practitioner or more than 1 approved pathology practitioner; or

  • (vi)

    are rendered on the same or different days; or

  • (b)

    a pathology service to which rule 4 refers that is provided in the circumstances set out in that rule that relates to the service.

recognised pathologist means a medical practitioner recognised as a specialist in pathology by a determination under section 3D or subsection 61 (3) of the Act.

serial examinationsmeans a series of examinations requested on 1 occasion whether or not:

  • (a)

    the materials are received on different days by the approved pathology practitioner; or

  • (b)

    the examinations or cultures were requested on 1 or more request forms by the treating practitioner.

the Act means the Health Insurance Act 1973.

(2)

In these Rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16A (6) of the Act applies.

(3)

A reference in this Table by number to an item that is not included in this Table is a reference to the item that has that number in the general medical services table or the diagnostic imaging services table, as the case requires.

(4)

A reference to a Group in the Table includes every item in the Group.

2Precedence of items
  • (1)

    If a service is described:

    • (a)

      in an item in general terms; and

    • (b)

      in another item in specific terms;

     only the item that describes the service in specific terms applies to the service.

  • (2)

    Subject to subrule (3), if:

    • (a)

      subrule (1) does not apply; and

    • (b)

      a service is described in 2 or more items;

     only the item that provides the lower or lowest fee for the service applies to the service.

  • (3)

    If an item is expressed to include a pathology service that is described in another item, the other item does not apply to the service in addition to the first-mentioned item, whether or not the services described in the 2 items are requested separately.

3Circumstances in which services rendered following 2 requests to be taken to have been rendered following 1 request

 (1) In subrule 3 (2), service includes assay, estimation and test.

7 (2)Two or more pathology services (other than services to which, under rule 4, this rule does not apply) rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:

  • (a)

    the services are listed in the same item; and

  • (b)

    the patient’s need for the services was determined under subsection 16A (1) of the Act on the same day even if the services are rendered by an approved pathology practitioner on more than one day.

4Services to which rule 3 does not apply
  • (1)

    Rule 3 does not apply to a pathology service described in item 66201, other than an estimation of fructosamine or lithium, if:

    • (a)

      the service is rendered in relation to a single specimen taken on each of not more than 4 occasions in a period of 24 hours; and

    • (b)

      the service is rendered to a patient in a hospital unit where:

      • (i)

        the presence of 1 nurse is required for each group of not more than 4 patients; and

      • (ii)

        the condition of the patients is continuously observed in relevant respects; and

    • (c)

      in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member; and

    • (d)

      the account for the service is endorsed Rule 3 Exemption.

  • (2)

    Rule 3 does not apply to any of the following pathology services:

    • (a)

      estimation of prothrombin time (INR) in respect of a patient undergoing anticoagulant therapy;

    • (b)

      quantitative estimation of lithium in respect of a patient undergoing lithium therapy;

    • (c)

      a service described in item 65007 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;

    • (d)

      a service described in item 65007 in relation to clozaril, ticlopidine hydrochloride, methotrexate, gold, sulfasalazine or penicillamine therapy of a patient;

    • (e)

      a service described in item 66201 in relation to methotrexate therapy of a patient;

    • (f)

      quantitative estimation of urea, creatinine and electrolytes in relation to:

      • (i)

        cis-platinum therapy of a patient; or

      • (ii)

        chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital;

    • (g)

      quantitative estimation of albumin and calcium in relation to therapy of a patient with vitamin D, its metabolites or analogues;

     if:

    • (h)

      under a request for a service, other than a request for a service described in paragraph (a), no more than 6 tests are requested; and

    • (i)

      the tests are performed within 6 months of the request; and

    • (j)

      the account for the service is endorsed Rule 3 Exemption.

5Item taken to refer only to the first service of a particular kind

 For an item in Group P1 (Haematology):

  • (a)

    if pathology services of a kind referred to in item 65017 or 65019 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during the period; and

  • (b)

    if:

    • (i)

      tests (except tests mentioned in item 65023) are carried out in relation to a patient episode; and

    • (ii)

      specimen material from the patient episode is stored; and

    • (iii)

      in response to a request made within 14 days of the patient episode, further tests (except tests mentioned in item 65023) are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

6Certain items not to apply to a service referred by one pathology practitioner to another
  • (1)

    In this rule:

    designated pathology service means a pathology service in respect of tests relating to a single patient episode that are:

    • (a)

      tests of the kind described in item 66235; or

    • (b)

      tests of the kind described in item 66405; or

    • (c)

      tests of the kind described in item 69229.

  • (2)

    This rule applies in respect of a designated pathology service where:

    • (a)

      an approved pathology practitioner (practitioner A) in an approved pathology authority:

      • (i)

        has been requested to render the designated pathology service; and

      • (ii)

        is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more (but not all) of the tests included in the service; and

      • (iii)

        requests an approved pathology practitioner (practitioner B) in another approved pathology authority to render the test or tests that practitioner A is unable to render; and

      • (iv)

        renders each test included in the service, other than the test or tests in respect of which the request mentioned in subparagraph (iii) is made; and

    • (b)

      the tests mentioned in subparagraph (a) (iv) that practitioner A renders are not tests constituting a service described in item 66239, 66415 or 69239.

  • (3)

    Where this rule applies in respect of a designated pathology service:

    • (a)

      item 66235, 66237, 66405, 66407, 66409, 66411, 66413, 69229, 69231, 69233, 69235 or 69237 (as the case requires) applies in respect of the test or tests rendered by practitioner A; and

    • (b)

      where practitioner B renders a service under a request referred to in subparagraph (2) (a) (iii) — subject to subrule (4), the amount specified in item 66241, 66417 or 69241 (as the case requires) is payable for each test that the service comprises.

     (4)For paragraph (3) (b), the maximum number of tests to which item 66241, 66417 or 69241 applies is:

    • (a)

      for item 66241:

      3 – X; or

    • (b)

      for item 66417 or 69241:

     6 – X;

     where X is the number of tests rendered by practitioner A in relation to the designated pathology service in respect of which the request mentioned in that paragraph is made.

  • (5)

    Items in Group P10 (Patient episode initiation) do not apply to the second-mentioned approved pathology practitioner in subrule (2).

7Items not to be split

 Except as stated in rule 6, the amount specified in an item is payable only to one approved pathology practitioner in respect of a single patient episode.

8Certain tests on stored material to be treated as part of the same patient episode

 For items in Group P2 (Chemical):

  • (a)

    if a pathology service that involves the measurement of a substance in urine requires calculation of a substance/creatinine ratio, the service is taken to include the measurement of creatinine necessary for the calculation; and

  • (b)

    if:

    • (i)

      tests are carried out in relation to a patient episode; and

    • (ii)

      specimen material from the patient episode is stored; and

    • (iii)

      in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

9Item 66317

 The amount specified in item 66317 is not payable in respect of a pathology service described in the item unless at least one of the following paragraphs applies:

  • (a)

    if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a serum cholesterol level >5.5 mmol/L — the determination is performed on the sample that the serum cholesterol level determination for the patient was performed;

  • (b)

    if the HDL cholesterol or apolipoprotein B/A1 ratio of the patient is requested to be determined because the patient has a fasting serum triglyceride level >2.0 mmol/L — the determination is performed on the sample that the serum triglyceride level determination for the patient was performed;

  • (c)

    the pathologist who renders the service has a written statement from the medical practitioner who requested the service that the patient is on a lipid lowering drug.

10Thyroid function testing
  • (1)

    For item 66329:

    abnormal level of TSH means a level of TSH that is outside the normal reference range in respect of the particular method of assay used to determine the level.

  • (2)

    Except where paragraph (a) of item 66329 is satisfied, the amount specified in the item is not payable in respect of a pathology service described in the item unless the pathologist who renders the service has a written statement from the medical practitioner who requested the service that satisfies subrule (3).

  • (3)

    The written statement from the medical practitioner must indicate:

    • (a)

      that the tests are required for a particular purpose, being a purpose specified in paragraph (b) of item 66329; or

    • (b)

      that the medical practitioner who requested the tests suspects the patient has pituitary dysfunction; or

    • (c)

      that the patient is on drugs that interfere with thyroid hormone metabolism or function.

11Meaning of serial examinations or cultures

 For an item in Group P3 (Microbiology):

  • (a)

    serial examinations or cultures means a series of examinations or cultures requested on 1 occasion whether or not:

    • (i)

      the materials are received on different days by the approved pathology practitioner; or

    • (ii)

      the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and

  • (b)

    if:

    • (i)

      tests are carried out in relation to a patient episode; and

    • (ii)

      specimen material from the patient episode is stored; and

    • (iii)

      in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

12Investigation for hepatitis and syphilis serology
  • (1)

    A medicare benefit is not payable in respect of more than one of items 69266, 69267, 69268, 69269, 69270, 69271, 69272, 69273, 69274, 69275, 69276, 69277, 69278, 69279, 69280, 69281 and 69283 in a patient episode.

  • (2)

    For items 69279 and 69283, currently elevated transaminase level means a level of alanine aminotransferase or aspartate aminotransferase above the normal reference range in respect of the particular method of assay used to determine the level, as disclosed by a test carried out on a sample taken for the investigation or on a sample taken within the previous 7 days.

13Tests in Group P4 (Immunology) relating to antibodies

 For items in Group P4 (Immunology), in items 71119, 71121, 71123 and 71125, if:

  • (a)

    tests are carried out in relation to a patient episode; and

  • (b)

    specimen material from the patient episode is stored; and

  • (c)

    in response to a request made within 14 days of the patient episode, further tests are carried out on the stored material;

 the later tests and the earlier tests are taken to be part of one patient episode.

14Tests on biopsy material – Group P5 (Tissue Pathology) and Group P6 (Cytology)
  • (1)

    For items in Group P5 (Tissue Pathology):

    • (a)

      biopsy material means all tissue (other than a bone marrow biopsy) received by an approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time; and

    • (b)

      if:

      • (i)

        a pathology service that comprises the examination of biopsy material is rendered under any of those items; and

      • (ii)

        a further pathology service mentioned in any of those items is also rendered using that biopsy material;

     those pathology services are taken to be 1 pathology service; and

    (c)cytology means microscopic examination of 1 or more stained preparations of cells separated naturally or artificially from their normal environment by methods recognised as adequate to demonstrate their structure to a degree sufficient to enable an opinion to be formed about whether they are likely to be normal, abnormal but benign, or abnormal and malignant but, in accordance with customary laboratory practice, does not include examination of a blood film and a bone marrow aspirate; and

    • (d)

      separately identified specimen means an individual specimen collected, identified so that it is clearly distinguished from any other specimen, and sent for testing by or on behalf of the treating practitioner responsible for the procedure in which the specimen was taken.

    (2)For Groups P5 and P6 of the Pathology Services Table, services in Group P6 include any services described in Group P5 on the material submitted for a test in Group P6.

  • (3)

    For subrule (2), any sample submitted for cytology from which a cell block is prepared does not qualify for a Group P5 item.

    (4)If more than 1 of the services mentioned in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 are performed in a single patient episode, a medicare benefit is payable only for the item performed that has the highest schedule fee.

  • (5)

    If more than 1 histopathological examinations are performed on separate specimens, of different complexity levels, from a single patient episode, a medicare benefit is payable only for the examination that has the highest schedule fee.

    (6)In items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 a reference to a complexity level is a reference to the level given to a specimen type mentioned in Part 4 of this Table.

15Items in Groups P10 (Patient episode initiation) and P11 (Specimen referred) not to apply in certain circumstances
  • (1)

    For this rule and items in Groups P10 (Patient episode initiation) and P11 (Specimen referred):

    institution means a place at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:

    • (a)

      disadvantaged children; or

    • (b)

      juvenile offenders; or

    • (c)

      aged persons; or

    • (d)

      chronically ill psychiatric patients; or

    • (e)

      homeless persons; or

    • (f)

      unemployed persons; or

    • (g)

      persons suffering from alcoholism; or

    • (h)

      persons addicted to drugs; or

    • (i)

      physically or mentally handicapped persons;

     but does not include:

    • (j)

      a hospital; or

    • (k)

      a nursing home; or

    • (l)

      accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex;

    licensed collection centre has the same meaning as in Part IIA of the Act.

    prescribed laboratory means a laboratory operated by:

    • (a)

      the Commonwealth; or

    • (b)

      a State or internal Territory; or

    • (c)

      an authority of a State or internal Territory; or

    • (d)

      an Australian tertiary education institution.

    specimen collection centre has the same meaning as in Part IIA of the Act.

    treating practitionerhas the same meaning as in paragraph 16A (1) (a) of the Act.

  • (2)

    If a service described in an item in Group P10 or P11 is rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist, the relevant one of those items does not apply to the service if:

    • (a)

      the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or

    • (b)

      the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request is made; or

    • (c)

      the pathology equipment of a recognised hospital, or a prescribed laboratory, is used rendering the service; or

    • (d)

      a member of the staff of a recognised hospital, or a prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.

  • (3)

    An item in Group P10 or P11 does not apply to a pathology service to which subsection 16A (7) of the Act applies.

  • (4)

    An item in Group P10 or P11 does not apply to a pathology service unless at least one item in Groups P1 to P8 also applies to the service.

  • (5)

    Subject to subrule (7), if one item in Group P10 applies to a patient episode, no other item in the Group applies to the patient episode.

  • (6)

    An item in Group P11 applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred.

  • (7)

    If, in respect of the same patient episode:

    • (a)

      services referred to in 1 or more items in Group P5 and 1 or more of Groups P1, P2, P3, P4, P6, P7 and P8 are rendered by an approved pathology practitioner in the laboratory of another approved pathology authority; and

    • (b)

      services referred to in 1 or more items in Group P6 and 1 or more of Groups P1, P2, P3, P4, P5, P7 and P8 are rendered by another approved pathology practitioner in another approved pathology authority;

     the fee specified in the applicable item in Group P10 is payable to both approved pathology practitioners.

  • (8)

    If more than one specimen is collected from a person on the same day for the provision of pathology services:

    • (a)

      in accordance with more than one request; and

    • (b)

      in or by a single approved pathology authority;

     only a single amount specified in the applicable item in Group P10 is payable for the services.

  • (9)

    The amount specified in item 73921 is payable only once in respect of a single patient episode.

16Application of an item in Group P11 (Specimen referred) to a service excludes certain other items

 If item 73921 applies to a patient episode, none of the items in Group P10 applies to any pathology service rendered by the approved pathology authority or approved pathology provider who claimed item 73921 in respect of the patient episode.

17Circumstances in which an item in Group P11 (Specimen referred) does not apply
  • (1)

    An item in Group P11 does not apply to a referral if:

    • (a)

      a service in respect of the same patient episode has been carried out by the referring approved pathology authority; and

    • (b)

      the approved pathology authority to which the referral is made is related to the referring approved pathology authority.

  • (2)

    An approved pathology authority is related to another approved pathology authority for subclause (1) if:

    • (a)

      both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or

    • (b)

      either of the approved pathology authorities is employed (including employed under contract) by the other; or

    • (c)

      both approved pathology authorities are corporations and are related corporations within the meaning of the Corporations Law; or

    • (d)

      the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities).

18Abbreviations
  • (1)

    The abbreviations in Part 3 of this Table may be used to identify particular pathology services or groups of pathology services.

  • (2)

    The names of services or drugs not listed in Part 3 of this Table must be written in full.

19Certain pathology services to be treated as one service
  • (1)

    In this rule:

    general practitioner means a medical practitioner who:

    • (a)

      is not a consultant physician in any specialty; and

    • (b)

      is not a specialist in any specialty.

    set of pathology services means a group of pathology services:

    • (a)

      that consists of services that are described in at least 4 different items; and

    • (b)

      all of which are requested in a single patient episode; and

    • (c)

      each of which relates to a patient who is not an admitted patient of a hospital; and

    • (d)

      none of which is referred to:

      • (i)

        in item 66241, 66417, 69241, 73053 or 73055; or

      • (ii)

        in an item in Group P10 (Patient episode initiation) or Group P11 (Specimen referred).

  • (2)

    If a general practitioner requests a set of pathology services, the pathology services in the set are to be treated as individual pathology services in accordance with this rule.

  • (3)

    If the fee specified in one item that describes any of the services in the set of pathology services is higher than the fees specified in the other items that describe the services in the set:

    • (a)

      the pathology service described in the first-mentioned item is to be treated as one pathology service; and

    • (b)

      either:

      • (i)

        the pathology service in the set that is described in the item that specifies the second-highest fee is to be treated as one pathology service; or

      • (ii)

        if 2 or more items that describe any of those services specify the second-highest fee — the pathology service described in the item that specifies the second-highest fee, and has the lowest item number, is to be treated as one pathology service; and

    • (c)

      the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

  • (4)

    If the fees specified in 2 or more items that describe any of the services in the set of pathology services are the same, and higher than the fees specified in the other items that describe the services in the set:

    • (a)

      the pathology service in the set that is described in the item that specifies the highest fee, and has the lowest item number, is to be treated as one pathology service; and

    • (b)

      the pathology service in the set that is described in the item that specifies the highest fee, and has the

      second-lowest item number, is to be treated as one pathology service; and

    • (c)

      the pathology services in the set, other than the services that are to be treated as one pathology service under paragraphs (a) and (b), are to be treated as one pathology service.

  • (5)

    If pathology services are to be treated as one pathology service under paragraph (3) (c) or (4) (c), the fee for the one pathology service is the highest fee specified in any of the items that describe the pathology services that are to be treated as the one pathology service.

20HIV viral RNA load testing

 For items 69259 and 69260, no more than a maximum of 6 episodes for either item 69259 or item 69260, or any combination for both items, can be claimed in a 12 month period.

21Hepatitis C viral RNA testing

 For item 69284:

Hepatitis C sero-positive, for a patient, means 2 different assays of Hepatitis C antibodies are positive.

serological status is uncertain, for a patient, means any result where 2 different assays of Hepatitis C antibodies are inconclusive.

22Haemochromatosis testing

 For item 66435:

elevated serum ferritin, for a patient, means a level of ferritin above the normal reference range in respect of the particular method of assay used to determine the level.

Part2Services and fees

Item

Pathology service

Fee  ($)

Group P1 — Haematology

65001

Erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, or reticulocyte count — 1 or 2 tests

7.70

65003

3 or more tests described in item 65001, and calculation or measurement of cell index or indices

10.25

65005

Examination of blood film, or 5 part differential cell count, or both 5 part differential cell count and examination of blood film, including

(if performed):

  • (a)

    a service described in item 65027; and

  • (b)

    any of the following services:

    • (i)

      examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron;

    • (ii)

      examination of a blood film with alpha-napthyl acetate esterase, chloroacetate esterase, neutrophil alkaline phosphatase, nitroblue tetrazolium, periodic acid Schiff or Sudan Black stains or acid elution stains

10.25

65007

Full blood examination (consisting of the services described in items 65003 and 65005)

17.20

65009

Haemolysis or metabolic enzymes — assessment by:

  • (a)

    erythrocyte autohaemolysis test;

  • (b)

    erythrocyte fragility test;

  • (c)

    sugar water test;

  • (d)

    erythrocyte metabolic enzyme test;

  • (e)

    heat denaturation test;

  • (f)

    isopropanol precipitation test;

  • (g)

    acid haemolysis test; and

  • (h)

    quantitation of muramidase in serum or urine;

1 or more tests

33.30

65011

Haemoglobinopathy, tests for the diagnosis of, consisting of haemoglobin electrophoresis and 2 of:

  • (a)

    examination for HbH; or

  • (b)

    quantitation of HbA2; or

  • (c)

    quantitation of HbF;

including a service described in item 65001, 65003, 65005 or 65007 (if performed)

57.80

65013

Bone marrow trephine biopsy — histopathological examination of sections of bone marrow, including (if performed):

  • (a)

    examination of aspirated material; and

  • (b)

    special stains or immunochemical techniques (if any); and

  • (c)

    a service described in item 65001, 65003, 65005, 65007 or 65015

163.70

65015

Bone marrow — examination of aspirated material (including clot sections where necessary), including (if performed):

  • (a)

    special stains or immunochemical techniques (if any); and

  • (b)

    a service described in item 65001, 65003, 65005 or 65007

82.00

65017

Blood grouping (including back-grouping if performed) — ABO and Rh (D antigen)

9.90

65019

Blood grouping — Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system — 1 or more systems, including a service described in item 65017 (if performed)

19.75

65021

Blood grouping (including back-grouping if performed), and examination of serum for Rh and other blood group antibodies, including:

  • (a)

    identification and quantitation of any antibodies detected; and

  • (b)

    (if performed) a service described in item 65001, 65003, 65005 or 65007

36.75

65023

Compatibility tests — all tests performed on any

1 day, including:

  • (a)

    all grouping checks of patient and donor; and

  • (b)

    examination for antibodies, and, if necessary, quantitation of any antibodies detected; and

  • (c)

    a service described in item 65001, 65003, 65005, 65007, 65017 or 65021 (if performed)

99.75

65025

Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected)

20.80

65027

1 or more of the following tests:

  • (a)

    direct Coombs test;

  • (b)

    qualitative or quantitative test for cold agglutinins or heterophile antibodies;

  • (c)

    qualitative spectroscopic examination of blood for abnormal haemoglobins;

  • (d)

    qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test)

8.95

65029

Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of: fibrinogen degradation products, fibrin monomer or D-dimer — 1 test

12.40

65031

2 tests described in item 65029

16.40

65033

3 tests described in item 65029

20.40

65035

4 or more tests described in item 65029

24.40

65037

Quantitation, by 1 or more techniques, of: plasminogen, antithrombin III, Protein C, Protein S, heparin cofactor II euglobulin clot lysis time and test for lupus anticoagulant — 1 to 3 tests

35.80

65039

4 or more tests described in item 65037

80.80

65041

Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance — 1 or more tests

55.80

65043

Heparin quantitation when monitoring a patient on subcutaneous heparin or low molecular weight heparin — 1 or more tests

32.50

65045

Quantitation of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, or Passovy factor — 1 test

48.80

65047

2 tests described in item 65045

95.80

65049

3 or more tests described in item 65045

140.80

65052

Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test) including any service described in item 65005 (if performed)

10.25

65053

Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell surface antigens using flow cytometric methods including any service described in item 65007 or 65052 (if performed)

34.00

Group P2 — Chemical

66201

Quantitation in serum, plasma, urine or other body fluid, by any method except reagent tablet or reagent strip (with or without reflectance meter or electrophoresis) of: alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total), bilirubin (any fractions), calcium (total, dialysed or ionised), chloride, creatine kinase, creatine kinase isoenzymes (if not performed as described in item 66249), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, urate or urea — 1 test

9.55

66203

2 tests described in item 66201

11.60

66205

3 tests described in item 66201

13.65

66207

4 tests described in item 66201

15.70

66209

5 tests described in item 66201

17.75

66211

6 or more tests described in item 66201

19.80

66213

Test by any method (except reagent strip or

dip-stick):

  • (a)

    for the presence of:

    • (i)

      the following urine constituents — bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen; or

    • (ii)

      cryoglobulins or cryofibrinogen in plasma; or

  • (b)

    of pH of body fluids other than urine (not including urine acidification test);

1 or more tests

13.00

66215

Quantitation of cryoglobulins or cryofibrinogen following their detection in a test described in item 66213, including that service — 1 or more tests

20.45

66223

Osmolality, estimation by osmometer, in serum or in urine — 1 or more tests

24.35

66225

Quantitation of:

  • (a)

    blood gases (including pO2, oxygen saturation and pCO2); and

  • (b)

    bicarbonate and pH;

including any other measurement (e.g. haemoglobin or potassium) or calculation performed on the same specimen — 1 or more tests on 1 specimen

33.25

66227

Quantitation of blood gases, bicarbonate and pH as described in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any 1 day

8.80

66229

Calculus, analysis of 1 or more

30.20

66231

All qualitative and quantitative tests on blood, urine or other body fluid for:

  • (a)

    a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or

  • (b)

    ingested or absorbed toxic chemicals;

     including a service described in item 66235, 66237 or 66239 (if performed), but excluding:

  • (c)

    the surveillance of sports people and athletes for performance improving substances; and

  • (d)

    the monitoring of patients participating in a drug abuse treatment program

41.00

66235

Quantitation, not elsewhere described in this Table by any method or methods, in blood or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test

(Item is subject to rule 6)

20.45

66237

2 tests described in item 66235

(Item is subject to rule 6)

28.65

66239

3 or more tests described in item 66235

36.85

66241

Tests described in item 66235, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 2 tests

(Item is subject to rule 6)

8.20

66243

Amniotic fluid, spectrophotometric examination of, and quantitation of:

  • (a)

    lecithin/sphingomyelin ratio; or

  • (b)

    palmitic acid, phosphatidylglycerol or lamellar body phospholipid;

1 or more tests

32.50

66247

Electrophoresis

(including quantitation), of serum and either or both urine or other body fluid all collected within a 28 day period, to demonstrate protein classes or presence of paraprotein, including the preliminary quantitation of:

  • (a)

    total protein, albumin and globulin; or

  • (b)

    total relevant enzyme activity;

2 or more tests

49.85

66249

Electrophoresis, quantitative or qualitative, of serum, urine or other body fluid to demonstrate:

  • (a)

    protein classes; or

  • (b)

    presence and amount of paraprotein; or

  • (c)

    the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase;

including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity

35.20

66250

Electrophoresis, quantitation or qualitative, of serum, for demonstration of lipoprotein subclasses, if the cholesterol is >6.5 mmol/l and triglyceride >3.0 mmol/l or in the diagnosis of types III and IV hyperlipidaemia — each episode to a maximum of

2 episodes in a 12 month period

30.20

66255

Alpha-1-acid glycoprotein, alpha-1-antitrypsin, or alpha-2-macroglobulin — quantitation in serum, urine or other body fluid — 1 or more tests

19.90

66257

C-1 esterase inhibitor — quantitation

19.90

66258

C-1 esterase inhibitor — functional assay

44.50

66261

CA-125 antigen, CA-15.3 antigen, CA-19.9 antigen, carcinoembryonic antigen (CEA), mammary serum antigen, mucin-like carcinoma-associated antigen (1 or more fractions), neuron-specific enolase, or thyroglobulin in serum or other body fluid, in the monitoring or confirmation of malignancy — quantitation — 1 test

19.90

66262

2 or more tests described in item 66261

36.65

66263

Iron studies, consisting of quantitation of:

  • (a)

    serum iron;

  • (b)

    transferrin or iron binding capacity; and

  • (c)

    ferritin

36.70

66265

Serum B12 or serum folate — 1 or more tests within a 28 day period

24.35

66267

Red cell folate and serum B12, and, if required, serum folate, to a maximum of 3 episodes in a 12 month period

44.45

66269

Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C, and E in blood, urine or other body fluid — 1 or more tests within a 6 month period

30.20

66271

Vitamin D or D fractions — 1 or more tests

37.90

66277

Quantitation of aluminium (except if item 66325 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, or strontium, in blood, urine or other body fluid or tissue — 1 or more tests in a 6 month period

35.35

66279

Blood lead quantitation (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period — each test

30.20

66281

Porphyrins (1 or more fractions), catecholamines

(1 or more fractions), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), or phenylacetic acid (PAA) — quantitation — 1 or more tests

39.45

66283

Quantitation of:

  • (a)

    faecal fat; or

  • (b)

    breath hydrogen in response to loading with disaccharides;

1 or more tests within a 28 day period

39.45

66285

Enzymes — quantitation of 1 or 2 in solid tissue or tissues other than blood elements

39.45

66287

Quantitation of 3 to 5 enzymes as described in

item 66285

73.45

66289

Quantitation of 6 or more enzymes as described in

item 66285

97.45

66293

Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and quantitation of hormones

54.50

66295

Personal performance by a recognised pathologist of 1 or more of the following:

  • (a)

    growth hormone suppression by glucose loading;

  • (b)

    growth hormone stimulation by exercise;

  • (c)

    dexamethasone suppression test;

  • (d)

    L-dopa stimulation of growth hormone

50.00

66297

Personal performance by a recognised pathologist of 1 of the following:

  • (a)

    gonadotrophin releasing hormone stimulation test;

  • (b)

    synacthen stimulation test;

  • (c)

    glucagon stimulation test with C-peptide measurement;

  • (d)

    pentagastrin stimulation of thyrocalcitonin release;

  • (e)

    secretin stimulation of gastrin release;

  • (f)

    insulin hypoglycaemia;

  • (g)

    arginine infusion

80.00

66299

Personal performance by a recognised pathologist of 2 or more tests described in item 66297

140.00

 

66315

Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests

78.90

66317

Quantitation of HDL cholesterol or apolipoprotein B/A1 ratio in a patient who:

  • (a)

    has a serum cholesterol level >5.5 mmol/l; or

  • (b)

    has a fasting serum triglyceride level >2.0 mmol/l; or

  • (c)

    is on a lipid lowering drug prescribed by a medical practitioner;

each episode to a maximum of 4 episodes in a 12 month period

(Item is subject to rule 9)

12.35

66319

Quantitation of glycosylated haemoglobin performed in the management of established diabetes — each test to a maximum of 4 tests in a 12 month period

16.60

66321

Quantitation, in the 2nd trimester of pregnancy, of alpha fetoprotein, human chorionic gonadotrophin, oestriol and any other substance to detect foetal abnormality, including a service described in 1 or more of items 66353, 66373, 73527 and 73529 (if performed) — 1 patient episode in a pregnancy

54.50

66322

Quantitation of glycosylated haemoglobin performed in the management of pre-existing diabetes where the patient is pregnant — each test to a maximum of 6 tests in a 12 month period which includes the whole pregnancy, including a service in item 66319 (if performed)

16.60

66323

Test for tryptic activity in faeces in the investigation of diarrhoea of longer than 4 weeks duration in children under 6 years old

11.00

66325

Quantitation of serum aluminium in a patient in a renal dialysis program — each test

35.35

66327

TSH quantitation

31.55

66329

Thyroid function tests (comprising the service described in item 66327 and 1 or more of the following tests — estimation of free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin) in respect of a patient, if at least one of the following conditions is satisfied:

  • (a)

    the patient has an abnormal level of TSH;

41.00

  • (b)

    the tests are performed for the purpose of:

    • (i)

      monitoring thyroid disease in the patient; or

    • (ii)

      if the patient is an admitted

      patient — investigating the sick euthyroid syndrome; or

  • (iii)

    investigating dementia or psychiatric illness of the patient; or

  • (iv)

    investigating amenorrhoea or infertility of the patient;

(c)

the medical practitioner who requested the tests suspects the patient has pituitary dysfunction;

(d)

the patient is on drugs that interfere with thyroid hormone metabolism or function

(Item is subject to rule 10)

66331

Quantitation (except by reagent strip with or without reflectance meter or electrophoresis) of cholesterol or triglycerides or both in serum, plasma, urine or other body fluid

11.40

66335

A service described in item 66331 and 1 test described in item 66201

13.65

66337

A service described in item 66331 and 2 tests described in item 66201

15.70

66339

A service described in item 66331 and 3 tests described in item 66201

17.75

66341

A service described in item 66331 and 4 or more tests described in item 66201

19.80

66343

Detection or quantitation or both (not including the detection of nicotine and metabolites in smoking withdrawal programs) of a drug, or drugs, of abuse or a therapeutic drug, on a sample collected from a patient:

  • (a)

    participating in a drug abuse treatment program; or

  • (b)

    being treated for drug effects;

including all tests on blood, urine or other body fluid — each episode, to a maximum of 21 episodes in a 12 month period

23.80

 

66353

Quantitation in serum or other body fluids of alpha fetoprotein, except if requested as part of item 66321

19.90

66355

Ferritin — quantitation, except if requested as part of iron studies

19.90

66357

Prostate specific antigen or prostatic acid phosphatase — quantitation in the confirmation or monitoring of malignancy — 1 test

19.90

66359

2 tests described in item 66357

36.65

66361

Beta-2-microglobulin, caeruloplasmin, haptoglobins, microalbumin in proven diabetes mellitus, or prealbumin — quantitation in serum, urine or other body fluids — 1 test

19.90

66363

2 or more tests described in item 66361

36.65

66367

Quantitation of acetoacetate, alcohol, amino acids, ammonia, angiotensin converting enzyme,

beta-hydroxybutyrate, cholinesterase, cysteine, total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline (except if performed as part of item 66425 or 66426), lactate, oxalate, pyruvate, serotonin, xylose, or zinc — 1 test

24.35

66369

2 or more tests described in item 66367

38.30

66373

Human placental lactogen or oestriol — quantitation, except if requested as part of item 66321 — 1 test

31.55

66375

2 tests described in item 66373

42.60

66405

Quantitation of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione,

C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(lgF1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test

(Item is subject to rule 6)

31.55

66407

2 tests described in item 66405

(Item is subject to rule 6)

42.55

66409

3 tests described in item 66405

(Item is subject to rule 6)

53.55

66411

4 tests described in item 66405

(Item is subject to rule 6)

64.55

66413

5 tests described in item 66405

(Item is subject to rule 6)

75.55

66415

6 or more tests described in item 66405

86.55

66417

Tests described in item 66405, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6 — each test to a maximum of 5 tests

(Item is subject to rule 6)

11.05

66419

Oral glucose tolerance test for the diagnosis of diabetes mellitus that includes the following:

  • (a)

    administration of glucose;

  • (b)

    at least 3 estimations of blood glucose;

  • (c)

    if performed, any test described in item 66405

17.70

66421

Test for reducing substances in faeces by any method (except reagent strip or dipstick)

6.50

66422

Examination for faecal occult blood (including tests for haemoglobin and its derivatives in the faeces) by:

  • (a)

    an immunological method; and

  • (b)

    a chemical method (except reagent strip or dip stick);

with a maximum of 3 examinations on specimens collected on separate days in a 28 day period — 1 examination by both methods

8.80

66423

2 examinations by both methods described in item 66422 performed on separately collected and identified specimens

17.60

66424

3 examinations by both methods described in item 66422 performed on separately collected and identified specimens

26.40

66425

Quantitation of products of collagen breakdown for the monitoring of patients with proven low bone mineral density, and if performed, a service described in item 66367 — 1 or more tests

24.35

66426

Quantitation of products of collagen breakdown for the monitoring of patients with metabolic bone disease, and if performed, a service described in item 66367 — 1 or more tests

24.35

66427

TSH quantitation described in item 66327 and 1 test described in item 66405

(Item is subject to rule 6)

42.55

66428

TSH quantitation described in item 66327 and 2 tests described in item 66405

(Item is subject to rule 6)

53.55

66429

TSH quantitation described in item 66327 and 3 tests described in item 66405

(Item is subject to rule 6)

64.55

66430

TSH quantitation described in item 66327 and 4 tests described in item 66405

(Item is subject to rule 6)

75.55

66431

TSH quantitation described in item 66327 and 5 tests described in item 66405

(Item is subject to rule 6)

86.55

66432

Tests described in items 66327 and 66405, if rendered under a request mentioned in subparagraph 2 (a) (iii) of rule 6 — each test to a maximum of 5 tests

(Item is subject to rule 6)

11.05

66435

Detection of the C282Y genetic mutation for haemochromatosis where:

  • (a)

    the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or

  • (b)

    the patient has a first degree relative with haemochromatosis or with homozygosity for the C282Y genetic mutation;

not exceeding 1 episode in a 3 year period

(Item is subject to rule 22)

36.00

Group P3 — Microbiology

69201

Microscopy of wet film material other than blood, from 1 or more sites, obtained directly from a patient (not cultures) including:

  • (a)

    differential cell count (if performed); or

  • (b)

    examination for dermatophytes; or

  • (c)

    dark ground illumination; or

  • (d)

    stained preparation or preparations, using any relevant stain or stains;

1 or more tests

8.15

69205

Culture and (if performed) microscopy to detect pathogenic micro-organisms (including fungi but excluding viruses), from nasal swabs, throat swabs, eye swabs and ear swabs, including (if performed):

  • (a)

    pathogen identification and antibiotic susceptibility testing; or

  • (b)

    the detection of antigens not elsewhere described in this Table; or

  • (c)

    a service described in item 69201;

specimens from 1 or more sites

21.50

69207

Microscopy and culture to detect pathogenic

micro-organisms, including fungi but excluding viruses, from:

  • (a)

    skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens); or

  • (b)

    specimens of sputum (except when part of item 69213);

including (if performed):

  • (c)

    the detection of antigens not elsewhere specified in this Table; or

  • (d)

    pathogenic identification and antibiotic susceptibility testing; or

  • (e)

    a service described in items 69201, 69205 and 73810;

1 or more tests on 1 or more specimens

33.00

69209

Microscopy and culture of postoperative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro-organisms (including fungi but excluding viruses) involving aerobic and anaerobic culture and the use of different culture media, and including (if performed):

47.00

  • (a)

    pathogen identification and antibiotic susceptibility testing; or

  • (b)

    the detection of antigens not elsewhere specified in this Table; or

  • (c)

    a service described in item 69201, 69205 or 69207;

specimens from 1 or more sites

69213

Microscopy with appropriate stains and culture of

3 specimens of sputum, urine or other body fluids for mycobacteria including (if performed):

  • (a)

    microscopy and culture of other bacterial pathogens; or

  • (b)

    pathogen identification and antibiotic susceptibility testing; and

  • (c)

    a service described in item 69201

125.00

69217

Urine examination (including serial examination) by any means other than simple culture by dip slide, including:

  • (a)

    cell count; and

  • (b)

    culture; and

  • (c)

    colony count (if performed); and

  • (d)

    stained preparations; and

  • (e)

    identification of cultured pathogens; and

  • (f)

    antibiotic susceptibility testing; and

  • (g)

    any examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts

20.55

69219

Detection of:

  • (a)

    the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus respiratory syncytial virus, cryptococcal antigens or Varicella zoster; or

  • (b)

    Clostridium difficile toxin (except if a service described in items 69289 to 69291 has been performed);

1 or more tests

25.00

69223

Detection of herpes simplex virus from material obtained directly from a patient (not cultures) — 1 or more tests

10.80

69229

Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in the Schedule — 1 test

13.90

(Item is subject to rule 6)

69231

2 tests described in item 69229

24.70

(Item is subject to rule 6)

69233

3 tests described in item 69229

34.70

(Item is subject to rule 6)

69235

4 tests described in item 69229

44.70

(Item is subject to rule 6)

69237

5 tests described in item 69229

54.70

(Item is subject to rule 6)

69239

6 or more tests described in item 69229

64.70

69241

Tests described in item 69229, if rendered under a request referred to in subparagraph (2) (a) (iii) of rule 6  — each test to a maximum of 5 tests

(Item is subject to rule 6)

10.80

69251

Antibiotics or antimicrobial chemotherapeutic agents in serum, urine or other body

fluid — quantitation — 1 or more tests

24.35

69253

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

  • (a)

    the determination of 1 of the following: rubella immune status, specific syphilis serology, hepatitis B surface antigen; and

  • (b)

    a service described in 1 or more of items 69229, 69266 to 69273, 69275 to 69278, 69280 and 69281 (if performed)

13.90

69255

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

  • (a)

    the determination of 2 of the following: rubella immune status, specific syphilis serology or hepatitis B surface antigen;

  • (b)

    a service described in 1 or more of items 69229, 69266 to 69273, 69275 to 69278, 69280 and 69281 (if performed)

24.70

69257

Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy) including:

  • (a)

    the determination of all 3 of the following: rubella immune status, specific syphilis serology and hepatitis B surface antigen; and

  • (b)

    a service described in 1 or more of items 69229, 69266 to 69273, 69275 to 69278, 69280 and 69281 (if performed)

34.70

69259

Quantitation of HIV viral RNA load in plasma, serum or cerebrospinal fluid in the monitoring of a HIV sero-positive patient, who is not on antiretroviral therapy — 1 or more assays on 1 or more specimens in any 1 episode to a maximum of 6 episodes in a 12 month period

(Item is subject to rule 20)

176.00

69260

Quantitation of HIV viral RNA load in plasma, serum or cerebrospinal fluid in the monitoring of antiretroviral therapy in a HIV sero-positive patient — 1 or more assays on 1 or more specimens

in any 1 episode to a maximum of 6 episodes in a 12 month period

(Item is subject to rule 20)

176.00

69262

Detection of Chlamydia by any method in specimens from 1 or more sites

19.85

69264

Examination for Herpes simplex virus of 1 or more types by culture in material obtained directly from a patient, including a service described in items 69223, 69262 or 69282 (if performed)

28.20

69266

Investigation for acute Hepatitis A using:

 Hepatitis A IgM antibody test

(Item is subject to rule 12)

13.90

69267

Determination of immune status to Hepatitis A using:

 Hepatitis A IgG antibody test

(Item is subject to rule 12)

13.90

69268

Investigation for acute or resolving Hepatitis B, or testing of close, recent contacts of proven Hepatitis B infection, including:

  • (a)

    Hepatitis B surface antigen test; and

  • (b)

    Hepatitis B core antibody test; and

  • (c)

    Hepatitis B e antibody test (if the Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive) (if performed)

(Item is subject to rule 12)

24.70

69269

Investigation for resolution of Hepatitis B if the Hepatitis B core antibody test is positive and the Hepatitis B surface antigen test is negative, including:

  • (a)

    Hepatitis B core antibody test; and

  • (b)

    Hepatitis B surface antigen test; and

  • (c)

    Hepatitis B surface antibody test

(Item is subject to rule 12)

34.70

69270

Determination of immune status to Hepatitis B (post exposure) using:

 Hepatitis B core antibody test

(Item is subject to rule 12)

13.90

69271

Determination of immune status to Hepatitis B (post vaccination) using:

 Hepatitis B surface antibody test

(Item is subject to rule 12)

13.90

69272

Investigation for chronic Hepatitis B or determination of carriage of Hepatitis B antigen using:

 Hepatitis B surface antigen test

(Item is subject to rule 12)

13.90

69273

Investigation for chronic Hepatitis B or carriage of Hepatitis B antigen if the Hepatitis B surface antigen test is positive, including:

  • (a)

    Hepatitis B surface antigen test; and

  • (b)

    Hepatitis B e antigen test

(Item is subject to rule 12)

24.70

69274

Testing for Hepatitis C using:

 Hepatitis C antibody test

(Item is subject to rule 12)

13.90

69275

Investigation for acute or chronic Hepatitis D in a patient with a positive Hepatitis B surface antigen test using:

 Hepatitis D antibody test

(Item is subject to rule 12)

13.90

69276

Determination of immune status to Hepatitis A and Hepatitis B, including:

  • (a)

    Hepatitis A IgG antibody test; and

  • (b)

    Hepatitis B core antibody test or Hepatitis B surface antibody test

(Item is subject to rule 12)

24.70

69277

Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, including:

  • (a)

    Hepatitis B surface antigen test; and

  • (b)

    Hepatitis C antibody test

(Item is subject to rule 12)

24.70

69278

Investigation for chronic viral hepatitis, or Hepatitis B or Hepatitis C carriage, if Hepatitis B surface antigen test is positive, including:

  • (a)

    Hepatitis C antibody test; and

  • (b)

    Hepatitis B surface antigen test; and

  • (c)

    Hepatitis B e antigen test

(Item is subject to rule 12)

34.70

69279

Investigation for acute Hepatitis A, Hepatitis B, Hepatitis C and Hepatitis D in a patient with a currently elevated transaminase level, including:

  • (a)

    Hepatitis A IgM antibody test; and

  • (b)

    Hepatitis C antibody test; and

  • (c)

    Hepatitis B surface antigen test; and

  • (d)

    Hepatitis B core antibody test; and

  • (e)

    Hepatitis B e antibody test (if Hepatitis B surface antigen test is negative and Hepatitis B core antibody test is positive) (if performed); and

  • (f)

    Hepatitis D antibody test (if Hepatitis B surface antigen test is positive) (if performed)

(Item is subject to rule 12)

44.70

69280

Determination of immune status to Hepatitis B and testing for Hepatitis C, including:

  • (a)

    Hepatitis C antibody test; and

  • (b)

    Hepatitis B core antibody test or Hepatitis B surface antibody test

(Item is subject to rule 12)

24.70

69281

Syphilis serology and any 1 of items 69273, 69274 or 69277

(Item is subject to rule 12)

34.70

69282

Microscopy and culture to detect pathogenic micro-organisms, including the detection of Chlamydia by any method from urethra, vagina, cervix or rectum and including (if performed):

  • (a)

    the detection of microbial antigens; or

  • (b)

    pathogen identification and antibiotic susceptibility testing; or

  • (c)

    a service described in item 69201, 69205, 69207, 69223, 69262, 69264 or 73810;

1 or more tests on 1 or more specimens

56.15

69283

Investigation for acute Hepatitis A and Hepatitis C in a patient with a currently elevated transaminase level, including:

  • (a)

    Hepatitis A IgM antibody test; and

  • (b)

    Hepatitis C antibody test

(Item is subject to rule 12)

27.45

69284

Detection of Hepatitis C viral RNA if at least 1 of the following criteria is satisfied:

  • (a)

    the patient is Hepatitis C sero‑positive and has normal liver function tests on 2 occasions 6 months apart;

  • (b)

    the patient’s serological status is uncertain after testing;

  • (c)

    the test is performed for the purpose of:

    • (i)

      determining the Hepatitis C status of an immunosuppressed or immunocompromised patient; or

    • (ii)

      the detection of acute Hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient;

not exceeding 1 episode in a 12 month period

(Item is subject to rule 21)

64.00

69285

Microscopy of faeces for parasites using concentration techniques (including the use of appropriate stains) with a maximum of

3 examinations on specimens collected on separate days, including a service (if performed) described in item 69201 — 1 examination

16.20

69286

2 examinations described in item 69285 performed on separately collected and identified specimens

32.40

69287

3 examinations described in item 69285 performed on separately collected and identified specimens

48.60

69289

Culture of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed):

  • (a)

    pathogen identification and antibiotic susceptibility testing; and

  • (b)

    the detection of clostridial toxins or antigens not elsewhere specified in this Table; and

  • (c)

    a service described in item 69201;

with a maximum of 3 examinations performed on separately collected and identified specimens in any 7 day period — 1 examination

51.65

69290

2 examinations described in item 69289 performed on separately collected and identified specimens

103.30

69291

3 examinations described in item 69289 performed on separately collected and identified specimens

154.95

69293

Blood culture for pathogenic micro-organisms (other than viruses), including sub-cultures and (if performed):

  • (a)

    identification of any cultured pathogen; and

  • (b)

    necessary antibiotic susceptibility testing;

to a maximum of 3 sets of cultures — 1 set of cultures

30.00

69294

2 sets of cultures described in item 69293

60.00

69295

3 sets of cultures described in item 69293

90.00

Group P4 — Immunology

71061

Immunoelectrophoresis or immunofixation, of serum, urine or other body fluid, and characterisation of, a paraprotein or cryoglobulin not previously characterised, including a service described in 1 or both of items 66213 and 66215 (if performed) — 1 or more tests

28.80

71063

Immunoelectrophoresis or immunofixation of serum and urine concurrently collected, and characterisation of, a paraprotein not previously characterised — 2 or more tests

43.45

71065

Examination of CSF and serum concurrently collected for the presence of oligoclonal proteins — 2 or more tests

43.45

71067

Quantitation of total immunoglobulins A, G, M or D by any method in serum, urine or other body fluid — 1 test

14.85

71069

2 tests described in item 71067

23.45

71071

3 or more tests described in item 71067

32.05

71073

Quantitation of all 4 immunoglobulin G subclasses — each patient episode

104.75

71075

Quantitation of immunoglobulin E (total), with a maximum of 2 patient episodes in a 12 month period — each patient episode

26.70

71077

Quantitation of immunoglobulin E (total) in the follow-up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in a 12 month period — each patient episode

26.70

71079

Detection of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in a 12 month period — each patient episode

24.10

71081

Quantitation of total haemolytic complement

19.90

71083

Quantitation of complement components C3 and C4 or properdin factor B — 1 test

19.90

71085

2 tests described in item 71083

28.55

71087

3 or more tests described in item 71083

37.20

71089

Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule — 1 test

28.75

71091

2 tests described in item 71089

52.10

71093

3 or more tests described in item 71089

75.45

71095

Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years

40.00

71097

Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required

25.10

71099

Double-stranded DNA antibodies — quantitation by 1 or more methods other than the Crithidia method

26.20

71101

Antibodies to 1 or more extractable nuclear antigens — detection in serum or other body fluids

17.15

71103

Characterisation of an antibody detected in a service described in item 71101 (including that service)

51.35

71106

Rheumatoid factor — detection by any technique in serum or other body fluids, including quantitation if required

11.15

71109

Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required, of 1 antibody

34.10

71113

Detection of 2 antibodies described in item 71109

46.80

71115

Detection of 3 antibodies described in item 71109

59.50

71117

Detection of 4 antibodies described in item 71109

72.20

71119

Antibodies to tissue antigens not elsewhere specified in this Table — detection, including quantitation if required, of 1 antibody

17.10

71121

Detection of 2 antibodies specified in item 71119

20.50

71123

Detection of 3 antibodies specified in item 71119

23.90

71125

Detection of 4 or more antibodies specified in item 71119

27.30

71127

Functional tests for lymphocytes — quantitation other than by microscopy of:

  • (a)

    proliferation induced by 1 or more mitogens; or

  • (b)

    proliferation induced by 1 or more antigens; or

  • (c)

    estimation of 1 or more mixed lymphocyte reactions;

including a test described in item 65005 (if performed), with a maximum of 2 patient episodes in a 12 month period — each patient episode

174.05

71129

2 tests described in item 71127

215.00

71131

3 or more tests described in item 71127

255.95

71135

Quantitation of neutrophil function, comprising at least 2 of the following:

  • (a)

    chemotaxis;

  • (b)

    phagocytosis;

  • (c)

    oxidative metabolism;

  • (d)

    bactericidal activity;

including any test described in item 65005 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in a

12 month period — each patient episode

205.25

71137

Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, with a maximum of 2 patient episodes in a 12 month period — each patient episode

29.85

71139

Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid

102.65

71141

Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens

194.80

71143

Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue

256.60

71145

Characterisation (but not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid

418.95

71147

HLA-B27 typing

32.00

71149

Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including a service described in item 71147 (if performed)

106.85

71151

Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens

117.30

Group P5 — Tissue pathology

72813

Examination of complexity level 2 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens

79.00

72816

Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen

84.50

72817

Examination of complexity level 3 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 or more separately identified specimens

94.50

72823

Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 separately identified specimen

95.00

72824

Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 2 to 4 separately identified specimens

105.00

72825

Examination of complexity level 4 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 5 or more separately identified specimens

115.00

72830

Examination of complexity level 5 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens

125.00

72836

Examination of complexity level 6 biopsy material with 1 or more tissue blocks, including specimen dissection, all tissue processing, staining, light microscopy and professional opinion or opinions — 1 or more separately identified specimens

150.00

72846

Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies

30.00

72847

Immunohistochemical examination of biopsy material by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies

40.00

72851

Electron microscopic examination of biopsy material — 1 separately identified specimen

150.00

72852

Electron microscopic examination of biopsy material — 2 or more separately identified specimens

200.00

72855

Intraoperative frozen section diagnosis of biopsy material — 1 separately identified specimen

150.00

72856

Intraoperative frozen section diagnosis of biopsy material — 2 or more separately identified specimens

200.00

Group P6 — Cytology

73043

Cytology (including serial examinations) of nipple discharge or smears from skin, lip, mouth, nose or anus for detection of precancerous or cancerous changes — 1 or more tests

19.80

73045

Cytology (including serial examinations) for malignancy (other than an examination mentioned in item 73053); and including any Group P5 service, if performed on:

  • (a)

    specimens resulting from washings or brushings from sites not specified in item 73043; or

  • (b)

    a single specimen of sputum or urine; or

  • (c)

    1 or more specimens of other body fluids;

1 or more tests

45.00

73047

Cytology of a series of 3 sputum or urine specimens for malignant cells

90.00

73049

Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues

65.00

73051

Cytology material obtained directly from a patient by fine needle aspiration of solid tissue or tissues if:

  • (a)

    the aspiration is performed by a recognised pathologist; or

  • (b)

    a recognised pathologist attends the aspiration and performs cytological examination during the attendance

163.85

73053

Cytology of smears from cervix:

  • (a)

    for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia; or

  • (b)

    due to an unsatisfactory smear taken in the circumstances defined in para (a) above; or

  • (c)

    if there is inadequate information provided to use item 73055;

each examination

17.80

73055

Cytology not associated with item 73053, of smears from cervix in association with:

  • (a)

    the management of previously detected abnormalities including precancerous or cancerous conditions; or

  • (b)

    the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia;

each test

17.80

73057

Cytology of smears from vagina, not associated with item 73053 or 73055 nor to monitor hormone replacement therapy — each test

17.80

73059

Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 1 to 3 antibodies

30.00

73060

Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049 and 73051 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 4 or more antibodies

40.00

GroupP7 — Cytogenetics

73287

Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of one or more of any tissue or fluid except blood — 1 or more tests

327.60

73289

Chromosome studies including preparation, count, karyotyping and identification by banding techniques or fragile X-site determination of blood — 1 or more tests

296.85

Group P8 — Infertility and pregnancy tests

73521

Semen examination for presence of spermatozoa, or examination of cervical mucus for spermatozoa (Huhner’s test)

6.80

73523

Semen examination (other than post-vasectomy semen examination), including:

  • (a)

    measurement of volume, sperm count, and motility; and

  • (b)

    examination of stained preparations; and

  • (c)

    morphology; and (if performed)

  • (d)

    differential count and 1 or more chemical tests;

with a maximum of 4 episodes in a 12 month period — each episode

35.80

73525

Sperm antibodies — sperm-penetrating ability — 1 or more tests

18.20

73527

Chorionic gonadotrophin (beta-HCG) —

 detection in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy — 1 or more tests

9.90

73529

Chorionic gonadotrophin (beta-HCG) — quantitation in serum by 1 or more methods (except by latex, membrane, strip or other pregnancy test kit) for diagnosis of hydatidiform mole, HCG-secreting neoplasm, or threatened abortion, or follow-up of abortion or diagnosis of ectopic pregnancy, including any services performed in 73527 — 1 test

28.25

Group P9 — Simple basic pathology tests

73801

Semen examination for presence of spermatozoa

6.75

73802

Leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count), haemoglobin, haematocrit or erythrocyte count — 1 test

4.45

73803

2 tests described in item 73802

6.20

73804

3 or more tests described in item 73802

7.95

73805

Microscopy of urine whether stained or not, or catalase test

4.45

73806

Pregnancy test by 1 or more immunochemical methods

9.90

73807

Microscopy for wet film other than urine, including any relevant stain

6.75

73808

Microscopy of Gram-stained film, including (if performed) a service described in item 73805 or 73807

8.45

73809

Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method

2.30

73810

Microscopy for fungi in skin, hair or nails — 1 or more sites

6.75

73811

Mantoux test

10.95

Group P10 — Patient episode initiation

73901

Initiation of a patient episode that consists only of a service described in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory

7.95

73903

Initiation of a patient episode that consists only of

 1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is an in-patient of a hospital other than a recognised hospital

14.15

73905

Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72823, 72824, 72825, 72830 and 72836 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital

7.85

73907

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in

Group P9) if the specimen is collected in a licensed collection centre

16.55

73909

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital

16.55

73910

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903 or 73905, or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in the place where the person was residing

10.15

73912

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903 or 73905, or in Group P9) if the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person in a nursing home or institution

10.15

73913

Initiation of a patient episode by collection of a specimen for a service (other than a service described in item 73901, 73903, 73905 or 73907 or items in Group P9) if the specimen is collected from the person by the person

10.15

73915

Initiation of a patient episode by collection of a specimen for a service (other than a service described in items 73901, 73903 or 73905 or items in Group P9) if the specimen is collected by or on behalf of the treating practitioner

10.15

Group P11 — Specimen referred

73921

Receipt of specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of a different approved pathology authority or another approved pathology authority

(Item is subject to subrule 15 (9))

10.15

Part3Abbreviations

Division AAbbreviations for groups of tests

Group

Tests included in group

Abbreviation

Items

Cardiac enzymes

Lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and creatine kinase (CK)

CE

66205

Coagulation studies

Prothrombin time, activated partial thrombo-plastin time and two or more of the following tests — bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer,

D-dimer, factor XIII screening tests

COAG

65035

Electrolytes

Sodium (NA), potassium (K), chloride (Cl), and bicarbonate (HCO3)

E

66207

Lipid studies

Cholesterol (CHOL) and triglycerides (TRIG)

FATS

66331

Liver function tests

Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), bilirubin (BIL), gamma glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), and protein (PROT)

LFT

66211

Syphilis serology

Rapid plasma reagin test (RPR), or venereal disease research laboratory test (VDRL), and treponema pallidum haemagglutination test (TPHA), or fluorescent treponemal antibody-absorption test (FTA)

STS

69231

Urea, electrolytes, creatine

Urea, electrolytes, creatinine

U&E

66211

Division BAbbreviations for individual tests

Test

Abbreviation

Item

Abnormal haemoglobins

AH

65027

Acetoacetate

ACAT

66367

Acetylcholine receptor — tissue antigens — antibodies

ARA

71109

Actinomycetes — microbial antibody testing

ACT

69229

Adenovirus — microbial antibody testing

ADE

69229

Adrenal cortex — tissue antigens — antibodies

ADR

71109

Adrenocorticotrophic hormone (ACTH)

ACTH

66405

AFB microscopy and culture of sputum

AFB

69213

Alanine aminotransferase

ALT

66201

Albumin

ALB

66201

Alcohol (ethanol)

ETOH

66367

Aldosterone

ALDS

66405

Alkaline phosphatase

ALP

66201

Alkaline phosphatase — isoenzymes

ALPI

66249

Alpha fetoprotein

AFP

66353

Alpha fetoprotein — for Down’s syndrome and neural tube defect testing

NTDD

66321

Alpha‑1‑acid glycoprotein

AAG

66255

Alpha-1-antitrypsin

AAT

66255

Alpha‑2‑macroglobulin

AMG

66255

Aluminium

AL

66277

Aluminium — renal dialysis

ALR

66325

Amino acids

AA

66367

Amiodarone

AMIO

66235

Amitriptyline

AMIT

66235

Ammonia

NH3

66367

Amniotic fluid examination

AFE

66243

Amylase

AMS

66201

Amylobarb

AMYL

66235

Androstenedione

ANDR

66405

Angiotensin converting enzyme

ACE

66367

Antibiotic and antimicrobial chemotherapeutic agents — quantitation

QAA

69251

Antibodies to extractable nuclear antigens — detection

ENA

71101

Antibodies to extractable nuclear antigens — characterisation of antibodies if positive ENA

ENAP

71103

Antibodies to nuclear antigens — detection

ANA

71097

Antibodies to nuclear antigens — quantitation and measurement of DNA binding if positive ANA

ANAP

71099

Antibodies to tissue antigens — acetylcholine receptor

ARA

71109

Antibodies to tissue antigens — adrenal cortex

ADR

71109

Antibodies to tissue antigens — cardiolipin

ACL

71109

Antibodies to tissue antigens — centromere

ACA

71119

Antibodies to tissue antigens — gastric parietal cell

PCA

71119

Antibodies to tissue antigens — gliadin IgA

GLIA

71119

Antibodies to tissue antigens — glomerular basement membrane

GBA

71109

Antibodies to tissue antigens — heart

AHE

71109

Antibodies to tissue antigens — histone

AHI

71109

Antibodies to tissue antigens — insulin receptor antibodies

INSA

71109

Antibodies to tissue antigens — intercellular cement substance of skin

ICCS

71109

Antibodies to tissue antigens — intrinsic factor

AIF

71109

Antibodies to tissue antigens — islet cell

AIC

71109

Antibodies to tissue antigens — Jo‑1

JO1

71119

Antibodies to tissue antigens — keratin

KERA

71119

Antibodies to tissue antigens — liver/kidney microsomes

LKA

71119

Antibodies to tissue antigens — lymphocyte

ALY

71109

Antibodies to tissue antigens — mitochondria

MA

71119

Antibodies to tissue antigens — neuron

ANE

71109

Antibodies to tissue antigens — neutrophil cytoplasm

ANCA

71109

Antibodies to tissue antigens — ovary

AOV

71109

Antibodies to tissue antigens — parathyroid

PTHA

71109

Antibodies to tissue antigens — platelet

APA

71109

Antibodies to tissue antigens — PM‑Sc1

PM1

71119

Antibodies to tissue antigens — reticulin

RCA

71119

Antibodies to tissue antigens — salivary gland

ASG

71109

Antibodies to tissue antigens — Scl‑70

SCL

71119

Antibodies to tissue antigens — skeletal muscle

SLA

71109

Antibodies to tissue antigens — skin basement membrane

SKA

71109

Antibodies to tissue antigens — smooth muscle

SMA

71119

Antibodies to tissue antigens — thyroglobulin

NCD

69229

Microbial antibody testing — parainfluenza 1

PF1

69229

Microbial antibody testing — parainfluenza 2

PF2

69229

Microbial antibody testing — parainfluenza 3

PF3

69229

Microbial antibody testing — paratyphi

PTY

69229

Microbial antibody testing — pertussis

PER

69229

Microbial antibody testing — poliomyelitis

PLO

69229

Microbial antibody testing — Proteus OX 19

POX

69229

Microbial antibody testing — Proteus OXK

POK

69229

Microbial antibody testing — Q fever

QFF

69229

Microbial antibody testing — rapid plasma reagin test

RPR

69229

Microbial antibody testing — respiratory syncytial virus

RSV

69229

Microbial antibody testing — Ross River virus

RRV

69229

Microbial antibody testing — rubella

RUB

69229

Microbial antibody testing — Salmonella typhi (H)

SAH

69229

Microbial antibody testing — Salmonella typhi (O)

SAO

69229

Microbial antibody testing — Schistosoma

STO

69229

Microbial antibody testing — streptococcal serology — anti‑DNASE B titre

ADNB

69229

Microbial antibody testing — streptococcal serology — anti‑streptolysin O titre

ASOT

69229

Microbial antibody testing — Streptococcus pneumoniae

PCC

69229

Microbial antibody testing — tetanus

TET

69229

Microbial antibody testing — Thermoactinomyces vulgaris

THE

69229

Microbial antibody testing — thermopolyspora

TPS

69229

Microbial antibody testing — Toxocara

TOC

69229

Microbial antibody testing — toxoplasma

TOX

69229

Microbial antibody testing — TPHA (Treponema pallidum haemagglutination test)

TPHA

69229

Microbial antibody testing — trichinosis

TOS

69229

Microbial antibody testing — typhus, Weil‑Felix

TYP

69229

Microbial antibody testing — Varicella zoster

VCZ

69229

Microbial antibody testing — VDRL (Venereal Disease Research Laboratory)

VDRL

69229

Microbial antibody testing — Yersinia enterocolitica

YER

69229

Microbial antigen testing — Chlamydia

CHLY

69262, 69282

Microbial antigen testing — Clostridium difficile

CLDT

69219

Microbial antigen testing — group B streptococcus

STB

69219

Microbial antigen testing — Haemophilus influenzae

HI

69219

Microbial antigen testing — herpes simplex virus

HSV

69223

Microbial antigen testing — Neisseria gonorrhoeae

GON

69219

Microbial antigen testing — Neisseria meningitidis

NMG

69219

Microbial antigen testing — respiratory syncytial virus

RSVN

69219

Microbial antigen testing — Streptococcus pneumoniae

SPN

69219

Microbial antigen testing — Varicella zoster

VCZN

69219

Micropolyspora faeni

MIC

69229

Microscopic examination of — faeces for parasites

OCP

69285-87

Microscopic examination of — material other than blood

M

69201

Microscopy and culture of — material from nose, throat, eye or ear

MCS1

69205

Microscopy and culture of — material from skin, superficial sites, urethra, vagina, cervix or rectum

MCS2

69207

Microscopy and culture of — post‑op wounds, aspirations of body cavities, synovial fluid, CSF and op/biopsy specimens

MCS3

69209

Microscopy and culture of — specimens of sputum

MCS2

69207

Microscopy and culture of — specimens of sputum, urine or other body fluids for mycobacteria

AFB

69213

Microscopy and culture to detect pathogenic micro-organisms including chlamydia

MCS4

69282

Microscopy, culture, identification and sensitivity of urine

UMCS

69217

Mitochondria — tissue antigens — antibodies

MA

71119

Mouth — cytology on specimens from

SMCY

73043

Mucin‑like carcinoma-associated antigen

MCA1

66261

Mumps — microbial antibody testing

MUM

69229

Murray Valley encephalitis — microbial antibody testing

MVE

69229

Mycobacteria microscopy and culture of sputum

AFB

69213

Mycoplasma pneumoniae — microbial antibody testing

MYC

69229

Myoglobin in urine

UMY

66213

N‑acetyl procainamide

NAPC

66235

Neisseria gonorrhoeae — microbial antigen testing

GON

69219

Neisseria menigitidis antigens

NMG

69219

Neisseria menigitidis — microbial antibody testing

MEN

69229

Neisseria menigitidis — microbial antigen testing

NMG

69219

Neural tube defects and Down’s syndrome

NTDD

66321

Neuron — tissue antigens — antibodies

ANE

71109

Neuron specific enolase

NSEN

66261

Neutrophil cytoplasm — tissue antigens — antibodies

ANCA

71109

Neutrophil functions

NFT

71135

Newcastle disease — microbial antibody testing

NCD

69229

Nickel

NI

66277

Nipple discharge — cytology on specimens from

SMCY

73043

Nitrazepam

NITR

66235

Nordothiepin

NDIP

66235

Norfluoxetine

NFLE

66235

Nortriptyline

NORT

66235

Nose — cytology on specimens from

SMCY

73043

Nose — microscopy and culture of material

MCS1

69205

Nuclear antigens — detection of antibodies to

ANA

71097

Oestradiol

E2

66405

Oestriol

E3

66373

Oestriol — for Down’s syndrome and neural tube defect testing

NTDD

66321

Oestrone

E1

66405

Oligoclonal proteins

OGP

71065

Op/biopsy specimens — microscopy and culture of material from

MCS3

69209

Osmolality — serum or urine

OSML

66223

Ovary — tissue antigens — antibodies

AOV

71109

Oxalate

OXAL

66367

Oxazepam

OXAZ

66235

PAA (phenyl acetic acid)

PAA

66281

Palmitic acid in amniotic fluid

PALM

66243

Pap smear

CCR

73053

Papanicolaou test

CCR

73053

Paracetamol

PARA

66235

Parainfluenza 1 — microbial antibody testing

PF1

69229

Parainfluenza 2 — microbial antibody testing

PF2

69229

Parainfluenza 3 — microbial antibody testing

PF3

69229

Paraprotein investigation — by electrophoresis

EPPI

66249

Paraprotein investigation — by immunoelectrophoresis or immunofixation

PPRO

71061

Paraprotein investigation — on concurrently collected serum or urine

PPSU

71063

Paraquat

PARQ

66235

Parasites — microscopic examination of faeces

OCP

69285-87

Parathyroid hormone (PTH)

PTH

66405

Parathyroid — tissue antigens — antibodies

PTHA

71109

Paratyphi — microbial antibody testing

PTY

69229

Partial thromboplastin time

PTT

65029

Passovy factor

PF

65045

Patient episode initiation

PEI

73901‑15

Pentagastrin

PSTR

66297

Pentobarbitone

PENT

66235

Perhexiline

PHEX

66235

Pertussis — microbial antibody testing

PER

69229

pH measurement of body fluids other than urine

PH

66213

Phenobarbitone

PHBA

66235

Phensuximide

PHEN

66235

Phenylacetic acid

PAA

66281

Phenytoin

PHEY

66235

Phosphate

PHOS

66201

Phosphatidylglycerol

PTGL

66243

Plasminogen

PLAS

65037

Platelet — aggregation

PLTG

65041

Platelet — count

PLTC

65001

Platelet — tissue antigens — antibodies

APA

71109

PM‑Sc1 — tissue antigens — antibodies

PM1

71119

Poliomyelitis — microbial antibody testing

PLO

69229

Porphobilingen in urine

UPG

66213

Porphyrins — quantitative test, 1 or more fractions

PR

66281

Porphyrins in urine — qualitative test

UPR

66213

Potassium

K

66201

Prealbumin

PALB

66361

Prednisolone

PRED

66235

Pregnancy serology — 1 test

MSP1

69253

Pregnancy serology — 2 tests

MSP2

69255

Pregnancy serology — 3 tests

MSP3

69257

Pregnancy testing

73805

Pregnancy testing — diagnosis

HCG

73527

Pregnancy testing — diagnosis of specified conditions

HCGD

73529

Pregnancy testing — for diagnosis of Down’s syndrome and neural tube defect

NTDD

66321

Primidone

PRIM

66235

Procainamide

PCAM

66235

Progesterone

PROG

66405

Prolactin

PROL

66405

Prominal

PROM

66235

Propranolol

PPNO

66235

Prostate specific antigen

PSA

66357

Prostatic acid phosphatase

ACP

66357

Protein — C

PROC

65037

Protein — S

PROS

65037

Protein, quantitation of — alpha fetoprotein

AFP

66353

Protein, quantitation of — alpha fetoprotein — for Down’s syndrome and neural tube defect testing

NTDD

66321

Protein, quantitation of — alpha‑l‑antitrypsin

AAT

66255

Protein, quantitation of — alpha‑2‑macroglobulin

AMAC

66255

Protein, quantitation of — beta‑2‑microglobulin

BMIC

66361

Protein, quantitation of — C‑l esterase inhibitor

CEI

66257

Protein, quantitation of — caeruloplasmin

CPLS

66361

Protein, quantitation of — classes or paraprotein by electrophoresis

EPPI

66247

Protein, quantitation of — classes or presence and amount of paraprotein by electrophoresis

EPP2

66249

Protein, quantitation of — ferritin (see also Iron studies)

FERR

66355

Protein, quantitation of — haptoglobins

HGLB

66361

Protein, quantitation of — microalbumin

MALB

66361

Protein, total — quantitation of

PROT

66201

Proteus OX 19 — microbial antibody testing

POX

69229

Proteus OXK — microbial antibody testing

POK

69229

Prothrombin time

PT

65029

Pyruvate

PVTE

66367

Q fever — microbial antibody testing

QFF

69229

Quinalbarb

QUIB

66235

Quinidine

QUIN

66235

Quinine

QNN

66235

Rapid plasma reagin test — microbial antibody testing

RPR

69229

RAST

RAST

71079

Rectum — microscopy and culture of material from

MCS2

69207

Red blood cells — Kleihauer

KLEI

65005

Red cell folate and serum B12 and serum folate if required

RCF

66267

Red cell porphyrins — qualitative test

RCP

65027

Referred specimen fee

73921

Renin

REN

66405

Respiratory syncytial virus — microbial antibody testing

RSV

69229

Respiratory syncytial virus — microbial antigen testing

RSVN

69219

Reticulin — tissue antigens — antibodies

RCA

71119

Reticulocyte count

RETC

65001

Rheumatoid factor

RF

71106

Rheumatoid factor — quantitation

RFQ

71106

Ross River virus — microbial antibody testing

RRV

69229

RSV (respiratory syncytial virus) — microbial antigen testing

RSVN

69219

RSV (respiratory syncytial virus) — microbial antibody testing

RSV

69229

Rubella — serology

RUB

69229

Salicylate — aspirin

SALI

66235

Salivary gland — tissue antigens — antibodies

ASG

71109

Salmonella typhi (H) — microbial antibody testing

SAH

69229

Salmonella typhi (O) — microbial antibody testing

SAO

69229

Schistosoma — microbial antibody testing

STO

69229

Scl‑70 — tissue antigens — antibodies

SCL

71119

Secretin

SSGR

66297

Selenium

SE

66277

Semen examination

SEE

73523

Semen examination — for spermatozoa (post vasectomy)

SES

73521

Serology — in pregnancy (see Pregnancy serology)

Serotonin

5HT

66367

Serum — Bl2

B12

66265

Serum — folate (with Bl2)

FOL

66265

Serum — folate (with Bl2 red cell folate)

RCF

66267

Sex hormone binding globulin

SHBG

66405

Skeletal muscle — tissue antigens — antibodies

SLA

71109

Skin — cytology

SMCY

73043

Skin — microscopy and culture of material from

MCS2

69207

Skin basement membrane — tissue antigens — antibodies

SKA

71109

Smooth muscle — tissue antigens — antibodies

SMA

71119

Snake venom

HISS

66231

Sodium

NA

66201

Solid tissue or tissues — chemical assays

ENZS

66285

Solid tissue or tissues — cytology of fine needle aspiration

FNCY

73049

Solid tissue or tissues — cytology of fine needle aspiration by, or in presence of, pathologist

FNCP

73051

Somatomedin

SOMA

66405

Sotalol

SALL

66235

Specific IgG or IgE antibodies

RAST

71079

Specimen referred fee

73921

Sperm antibodies

SAB

73525

Sperm antibodies — penetrating ability

SPA

73525

Sputum — cytology (1 specimen)

BFCY

73045

Sputum — cytology (3 specimens)

SPCY

73047

Sputum — microscopy and culture of specimens

MCS2

69207

Sputum — for mycobacteria

AFB

69213

Stelazine

STEL

66235

Steroid fraction or fractions in urine

USF

66405

Streptococcal serology — anti‑DNASE B titre — microbial antibody testing

ADNB

69229

Streptococcal serology — anti‑streptolysin O titre — microbial antibody testing

ASOT

69229

Streptococcus — Group B

STB

69219

Streptococcus pneumoniae — antigens

SPN

69219

Streptococcus pneumoniae — microbial antibody testing

PCC

69229

Streptococcus pneumoniae — microbial antigen testing

SPN

69219

Strontium

SR

66277

Sulthiame (Ospolot)

SUL

66235

Synacthen stimulation test

SYNS

66297

Syphilis serology (see group tests)

STS

69231

Syphilis serology with 1 of 69273, 69274 or 69277

SHV

69281

Testosterone

TES

66405

Tetanus — microbial antibody testing

TET

69229

Thalassaemia studies

TS

65011

Theophylline

THEO

66235

Thermoactinomyces vulgaris — microbial antibody testing

THE

69229

Thermopolyspora — microbial antibody testing

TPS

69229

Thiopentone

TOPO

66235

Thioridazine

THIO

66235

Throat — microscopy and culture of material from

MCS1

69205

Thrombin time

TT

65029

Thyroglobulin

TGL

66261

Thyroglobulin — tissue antigens — antibodies

ATG

71109

Thyroid function tests (including TSH)

TFT

66329

Thyroid stimulating hormone (if requested on its own, or as a preliminary test to thyroid function testing)

TSH

66327

Thyroid stimulating hormone (if requested with other hormones referred to in item 66405))

TSH

66405

Thyroid microsome — tissue antigens — antibodies

TMA

71109

Thyrotrophin releasing hormone test

TRH

66293

Total free fatty acids

TFFA

66367

Total protein

PROT

66201

Toxocara — microbial antibody testing

TOC

69229

Toxoplasma — microbial antibody testing

TOX

69229

TPHA (Treponema pallidum haemagglutination test) — microbial antibody testing

TPHA

69229

Treponema pallidum haemagglutination test — microbial antibody testing

TPHA

69229

Trichinosis — microbial antibody testing

TOS

69229

Triglycerides

TRIG

66331

Trimipramine

TRIM

66235

Tryptic activity in faeces

TAF

66323

TSH receptor antibody test — tissue antigens — antibodies

TSHA

71109

Tuberculosis

MANT

73811

Tumour markers — CA‑15.3 antigen

CA15

66261

Tumour markers — CA‑19.9 antigen

CA19

66261

Tumour markers — CA‑125 antigen

C125

66261

Tumour markers — carcinoembryonic antigen

CEA

66261

Tumour markers — mammary serum antigen

MSA

66261

Tumour markers — mucin‑like carcinoma associated antigen

MCA

66261

Tumour markers — neuron specific enolase

NSEN

66261

Tumour markers — prostate specific antigen

PSA

66357

Tumour markers — prostatic acid phosphatase‑1 or more fractions

ACP

66357

Tumour markers — thyroglobulin

TGL

66261

Typhus, Weil‑Felix — microbial antibody testing

TYP

69229

Urate

URAT

66201

Urea

U

66201

Urea, electrolytes, creatinine (see group tests in Division A)

Urethra — microscopy and culture of material from

MCS2

69207

Urine — bilirubin

UBIL

66213

Urine — catalase test

UCAT

73805

Urine — cystine (cysteine)

UCYS

66213

Urine — cytology — on 1 specimen

BFCY

73045

Urine — cytology — on 3 specimens

SPCY

73047

Urine — haemoglobin

UHB

66213

Urine — melanin (melanogen)

UML

66213

Urine — microscopy, culture, identification and sensitivity

UMCS

69217

Urine — myoglobin

UMY

66213

Urine — porphobilinogen

UPG

66213

Urine — porphyrins — qualitative test

UPR

66213

Urine — steroid fraction or fractions

USF

66405

Urine — urobilinogen

UUB

66213

Vagina — cytology on specimens from

CVO

73057

Vagina — microscopy and culture of material from

MCS2

69207

Valproate (Epilim)

VALP

66235

Vancomycin

VAN

66235

Varicella zoster — microbial antibody testing

VCZ

69229

Varicella zoster — microbial antigen testing

VCZN

69219

Vasoactive intestinal peptide

VIP

66405

Vasopressin

ADH

66405

VDRL (Venereal Disease Research Laboratory) — microbial antibody testing

VDRL

69229

Viscosity of blood or plasma

VISC

65001

Vitamins — B12

RCF

66267

Vitamins — D

VITD

66271

Vitamins — folate

RCF

66267

Vitamins — quantitation of A, B1, B2, B3, B6, C or E

VIT

66269

VMA (see HMMA)

Von Willebrand’s factor

VWF

65045

Von Willebrand’s factor antigen

VWA

65045

Warfarin

WFR

66235

Xylose

XYL

66367

Yersinia enterocolitica — microbial antibody testing

YER

69229

Zinc

ZN

66367

Part4Complexity levels for histopathology items

Specimen Type

Complexity Level

Adrenal resection, neoplasm

5

Adrenal resection, not neoplasm

4

Aneurysm — all types

3

Anus, fissure or fistula

3

Anus, haemorrhoids

3

Anus tag

3

Appendix

3

Artery, atheromatous plaque

3

Artery, biopsy

4

Bartholin’s gland — cyst

3

Bile duct, resection — all specimens

6

Bone, biopsy, currettings or fragments — lesion

5

Bone, biopsy or currettings quantitation — metabolic disease

6

Bone, femoral head

4

Bone, resection, neoplasm — all sites and types

6

Bone marrow, biopsy

4

Bone — all specimens not otherwise specified

4

Brain neoplasm, resection — cerebello-pontine angle

4

Brain or meninges, biopsy — all lesions

5

Brain or meninges, not neoplasm — temporal lobe

6

Brain or meninges, resection — neoplasm (intracranial)

5

Brain or meninges, resection — not neoplasm

4

Branchial cleft, cyst

4

Breast, biopsy, excision — non-palpable malignant neoplasm

6

Breast, biopsy, excision — palpable malignant neoplasm

6

Breast, biopsy, needle with localization

6

Breast, mastectomy with nodes (including radical)

6

Breast tissue — not otherwise specified

4

Bronchus, biopsy

4

Carotid body — neoplasm

5

Cholesteatoma

3

Digits, amputation — not traumatic

4

Digits, amputation — traumatic

2

Endocrine neoplasm — not otherwise specified

5

Extremity, amputation or disarticulation — neoplasm

6

Extremity, amputation — not otherwise specified

4

Eye, conjunctiva — biopsy or pterygium

3

Eye, cornea

4

Eye, enucleation or exenteration — all lesions

5

Eye — not otherwise specified

4

Fallopian tube, biopsy

4

Fallopian tube, ectopic pregnancy

4

Fallopian tube, sterilization

2

Fetus with dissection

6

Foreskin — new born

2

Foreskin — not new born

3

Gallbladder

3

Gallbladder and porta hepatis — radical resection

6

Ganglion cysts

3

Glomus, neoplasm

4

Gum or oral mucosa, biopsy

4

Heart valve

4

Heart — not otherwise specified

5

Hernia sac

2

Hydrocele sac

2

Joint tissue including bone

4

Joint — all structures other than bone

3

Kidney, biopsy including transplant

5

Kidney, nephrectomy transplant

5

Kidney, partial or total nephrectomy or nephroureterectomy — neoplasm

5

Kidney, partial or total nephrectomy — not neoplasm

4

Large bowel, biopsy — all sites

4

Large bowel, colostomy — stoma

3

Large bowel, polyp

4

Large bowel, segmental resection — colon, not neoplasm

5

Large bowel (including rectum), neoplasm

6

Larynx, biopsy

4

Larynx, partial or total resection

5

Larynx, resection with nodes or pharynx or both

6

Lip, biopsy or wedge resection

4

Liver, hydatid cyst — resection for trauma

4

Liver — all specimens not otherwise specified

5

Lung, needle or transbronchial biopsy

4

Lung, resection — neoplasm

6

Lung, wedge biopsy

5

Lung segment, lobe or total — not neoplasm

5

Lymph node, biopsy — all sites

4

Lymph nodes, regional resection — all sites

5

Mediastinum mass

5

Muscle, biopsy

5

Nasopharynx or oropharynx, biopsy

4

Nerve, biopsy neuropathy

5

Nerve, neurectomy or removal of neoplasm

4

Nerve — not otherwise specified

3

Nose, mucosal biopsy

4

Nose or sinuses, polyps

3

Odontogenic neoplasm

5

Odontogenic or dental cyst

4

Oesophagus, biopsy

4

Oesophagus, diverticulum

3

Oesophagus, partial or total resection

6

Omentum, biopsy

4

Ovary with or without tube — neoplasm

5

Ovary with or without tube — not neoplasm

4

Pancreas, biopsy

5

Pancreas, cyst

4

Pancreas, subtotal or total with or without splenectomy

6

Parathyroid gland(s)

4

Penisectomy with node dissection

5

Penisectomy — simple

4

Periarticular tissue — ganglion cyst

3

Periarticular tissue — not otherwise specified

4

Peritoneum, biopsy

4

Pituitary neoplasm

4

Placenta — not third trimester

4

Placenta — third trimester, abnormal pregnancy or delivery

4

Pleura or pericardium, biopsy or tissue

4

Products of conception, spontaneous or missed abortion

4

Products of conception, termination of pregnancy

3

Prostate, radical resection

6

Prostate — all types of specimen not otherwise specified

4

Retroperitoneum, neoplasm

5

Salivary gland, Mucocele

3

Salivary gland, neoplasm — all sites

5

Salivary gland — all specimens not otherwise specified

4

Sinus, front nasal, ethmoidectomy

6

Sinus, paranasal, biopsy

4

Sinus, paranasal, resection — neoplasm

5

Skin, biopsy — blistering skin diseases

5

Skin, biopsy — inflammatory dermatosis

5

Skin, local resection — orientation or margins, at least 5cm long

4

Skin — all specimens not otherwise specified including all neoplasms

3

Small bowel, diverticulum

3

Small bowel, resection — neoplasm

6

Small bowel — all specimens not otherwise specified

4

Soft tissue, extensive resection at least 5cm long — neoplasm

6

Soft tissue, lipoma and variants

3

Soft tissue, neoplasm, not lipoma — all specimens

5

Soft tissue — not otherwise specified

4

Spleen

5

Stomach, biopsy

4

Stomach, resection, neoplasm — all specimens

6

Stomach — all specimens not otherwise specified

4

Tendon or tendon sheath, ganglion cyst

3

Tendon or tendon sheath, giant cell neoplasm

4

Tendon or tendon sheath — not otherwise specified

4

Testis, biopsy

5

Testis and adjacent structures, castration

2

Testis and adjacent structures, neoplasm with or without nodes

5

Testis and adjacent structures, vas deferens sterilization

2

Testis and adjacent structures — not otherwise specified

3

Thymus — not otherwise specified

5

Thyroglossal duct — all lesions

4

Thyroid — all specimens

5

Tissue or organ not otherwise specified, abscess

3

Tissue or organ not otherwise specified, haematoma

3

Tissue or organ not otherwise specified, malignant neoplasm with regional nodes

6

Tissue or organ not otherwise specified, neoplasm local

4

Tissue or organ not otherwise specified, pilonidal cyst or sinus

3

Tissue or organ not otherwise specified, thrombus or embolus

3

Tissue or organ not otherwise specified, veins varicosity

3

Tissue or organ — all specimens not otherwise specified

3

Tongue, biopsy

4

Tongue or tonsil, neoplasm local

5

Tongue or tonsil, neoplasm with nodes

6

Tonsil, biopsy — excluding resection of whole organ

4

Tonsil or adenoids or both

2

Trachea, biopsy

4

Ureter, biopsy

4

Ureter, resection

5

Urethra, biopsy

4

Urethra, resection

5

Urinary bladder, partial or total with or without prostatectomy

6

Urinary bladder, transurethral resection of neoplasm

5

Urinary bladder — all specimens not otherwise specified

4

Uterus, cervix, curettings or biopsy

4

Uterus, cervix cone, biopsy

5

Uterus, endocervix, polyp

4

Uterus, endometrium, polyp

4

Uterus with or without adnexa, malignant neoplasm — all specimen types not otherwise specified

5

Uterus with or without adnexa, neoplasm, Wertheim’s or pelvic clearance

6

Uterus — all specimens not otherwise specified

4

Vagina, biopsy

4

Vagina, radical resection

6

Vaginal mucosa, incidental

3

Vulva or labia, biopsy

4

Vulval, subtotal or total with or without nodes

6

Notes to the Health Insurance (1997-98 Pathology Services Table) Regulations

Note 1

The Health Insurance (1997-98 Pathology Services Table) Regulations (in force under the Health Insurance Act 1973) as shown in this compilation comprise Statutory Rules 1997 No. 299 amended as indicated in the Tables below.

Table of Statutory Rules

Year and

number

Date of notification

in Gazette

Date of

commencement

Application, saving or

transitional provisions

1997 No. 299

31 Oct 1997

1 Nov 1997

1998 No. 203

1 July 1998

1 July 1998

—

1998 No. 303

30 Oct 1998

1 Nov 1998

—

Table of Amendments

    ad. = added or inserted

     am. = amended rep. = repealed rs. = repealed and substituted

Provision affected

How affected

Schedule.................................

am. 1998 No. 203

Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0